Psychobiotics and Fermented Foods May Target the Gut-Brain Axis in Alzheimer’s Disease

A new review published in the journal Discover Aging examines whether psychobiotics — specific probiotic and prebiotic strains that influence the gut microbiome — and fermented foods could offer a nutritional route to influencing Alzheimer’s disease through the gut-brain axis. The review, authored by Hoda Bakr Mabrok and Doha Abdou Mohamed, brings together preclinical and clinical evidence on how gut microbes, their metabolites, and fermented products might interact with the biological processes that drive Alzheimer’s pathology. Its central conclusion is cautious but intriguing: animal studies consistently point to neuroprotective effects, while human evidence remains sparse, small, and heterogeneous, leaving clinical applicability and preventive efficacy in people uncertain and dependent on well-designed randomized controlled trials.

The biological rationale rests on the gut-brain axis, the bidirectional communication network linking the gut microbiota with the central nervous system. This network regulates immune responses, sleep, mood, food intake, and intestinal function through several channels: the vagus nerve, the hypothalamic-pituitary-adrenal (HPA) axis, microbial metabolites such as short-chain fatty acids, bacterial neurotransmitters including gamma-aminobutyric acid and catecholamines, and immune signaling through cytokine regulation. Gut microbiota has been shown to influence neuroinflammation, neurotransmitter production, and blood-brain barrier integrity — all processes implicated in Alzheimer’s disease. Dysbiosis, a disruption in the balance of the gut microbiome, may alter microbial composition and function in ways that connect to neurological and psychiatric conditions, including Alzheimer’s disease.

The review situates this within Alzheimer’s broader pathology. The disease is a chronic neurological disorder characterized by progressive brain atrophy, accumulation of amyloid-beta (Aβ) plaques, and tau tangles, and it is the most common form of dementia. Several hypotheses attempt to explain its progression: the amyloid hypothesis, in which an imbalance between Aβ synthesis and clearance drives plaque formation and neurotoxicity; the tau hypothesis, in which hyperphosphorylated tau detaches from microtubules and forms neurofibrillary tangles; the cholinergic hypothesis, in which declining acetylcholine neurotransmission contributes to cognitive decline; and chronic neuroinflammation, in which sustained activation of microglia and astrocytes releases pro-inflammatory cytokines that damage neurons. Dysbiotic gut microbiota may amplify these processes by increasing inflammatory mediators and impairing the permeability of the intestinal mucosa and the blood-brain barrier.

The scale of the problem gives the search for new interventions urgency. According to the World Health Organization figures cited in the review, more than 55 million people worldwide live with dementia, with Alzheimer’s accounting for the majority of cases, and this number is projected to rise to about 78 million by 2030 and 139 million by 2050. Current pharmacological treatments — cholinesterase inhibitors such as donepezil, galantamine, and rivastigmine, and the NMDA receptor antagonist memantine — provide only symptomatic relief and do not prevent or cure the disease. Against this backdrop, the authors argue, nutritional interventions that target disease-modifying mechanisms deserve systematic evaluation. Epidemiological and cohort research they cite suggests diet matters: a meta-analysis found that a healthy diet such as the Mediterranean diet is associated with an 11 to 30 percent lower risk of cognitive impairment and Alzheimer’s disease.

The preclinical evidence for psychobiotics is the strongest part of the review, and it is mechanistically rich. In an Alzheimer’s mouse model, treatment with Bifidobacterium breve inhibited the expression of genes related to oxidative stress and inflammation in the hippocampus. In rats given intrahippocampal injections of beta-amyloid, supplementation with B. lactis, B. longum, Lactobacillus fermentum, and L. acidophilus for eight weeks enhanced spatial memory and learning, decreased amyloid plaques, and lowered inflammation and oxidative stress markers in the hippocampus. Clostridium butyricum supplementation in Alzheimer’s-transgenic mice reduced cognitive impairments, Aβ deposition, and microglia-mediated neuroinflammation, lowering microglial activation and the production of interleukin-1β and tumor necrosis factor-alpha in the brain.

Other animal findings extend the mechanistic picture. Lactobacillus plantarum MTCC1325 given for 60 days in a D-galactose-induced rat model enhanced cognitive behavior, increased acetylcholine levels, and reduced acetylcholinesterase activity in the cortex and hippocampus, suggesting protection against cholinergic neuron degeneration. Bifidobacterium breve CCFM1025 and WX improved Aβ-induced memory defects in mice, decreased hippocampal Aβ accumulation, improved synaptic plasticity, and raised levels of brain-derived neurotrophic factor (BDNF) and transforming growth factor-beta. L. plantarum PS128 delayed disease progression in streptozotocin-induced mice by decreasing GSK-3β activity, phosphorylated tau levels, and Aβ deposition-related proteins. A recent study using an APP/PS1 transgenic mouse model tested a ten-strain human probiotic cocktail of five Lactobacillus and five Enterococcus species at a daily dose of 1 × 10¹¹ CFU for 16 weeks; it reduced Aβ aggregation, microglial activation, and neuroinflammation, improved performance in the Morris Water Maze, and preserved blood-brain barrier integrity by maintaining tight junction proteins.

Clinical evidence is far thinner. In one randomized, double-blind, controlled trial, 79 Alzheimer’s patients received L. acidophilus, B. bifidum, B. longum, and selenium for 12 weeks; mini-mental state examination scores significantly increased, along with total antioxidant capacity and total glutathione, while serum insulin, C-reactive protein, and triglycerides decreased. Another line of evidence concerns brain glucose metabolism: an eight-strain psychobiotic mixture given to Alzheimer’s triple-transgenic mice at 200 billion bacteria per kilogram per day for 16 weeks enhanced glucose uptake and decreased phosphorylated tau aggregates by restoring expression of the glucose transporters GLUT1 and GLUT3 and reducing phosphorylation of AMPK and Akt. The authors stress that these clinical data come from a small number of trials with limited sample sizes and heterogeneous interventions, and that larger, well-designed randomized controlled trials with standardized strains, defined dosages, and longer follow-up are required.

Fermented foods show a parallel pattern. In the 5xFAD mouse model, fermented camembert cheese reduced Aβ plaque accumulation, lowered inflammatory cytokines such as MIP-1α and TNF-α in the hippocampus, and elevated BDNF and glial cell line-derived neurotrophic factor. Milk kefir in lipopolysaccharide-induced rats upregulated BDNF and Bcl-2, reduced oxidative stress, improved cognition, and decreased Aβ and tau pathology. Tibetan fermented milk improved spatial learning and memory and reduced hippocampal and cortical Aβ deposition in transgenic mice, and a kefir-derived product containing L. kefiri reduced tau hyperphosphorylation and Aβ accumulation in a dose-dependent manner in streptozotocin-induced rats. Probiotic-fermented milk containing B. bifidum, L. helveticus, and L. casei enhanced cognitive function in model rats while upregulating PI3K and Akt genes — a signaling pathway whose Alzheimer’s-related inhibition promotes apoptosis, neuron death, and oxidative stress, and whose reactivation the review frames as a promising therapeutic target.

Human data on fermented foods are limited but suggestive. Alzheimer’s patients who consumed a fermented kefir milk formula for 90 days showed improved cognitive deficits, with reduced proinflammatory cytokines and oxidative stress biomarkers and gains in memory, abstraction, visual-spatial, executive, and language functions. Fermented papaya supplementation for six months decreased urinary 8-hydroxy-2′-deoxyguanosine, a marker of oxidative damage, in Alzheimer’s patients. A dose-response meta-analysis of 15 cohort studies with more than 300,000 participants found a negative nonlinear association between daily dairy intake and cognitive decline or dementia incidence, with the analysis suggesting a reference intake of 150 grams per day. In cognitively impaired populations, fermented soybean containing L. plantarum C29 and tempeh consumption were each associated with improved cognitive scores, and a double-blind, placebo-controlled randomized trial found that L. rhamnosus GG for three months increased cognitive scores in middle-aged and older adults with mild cognitive impairment.

The review also draws an important conceptual distinction and closes with safety caveats. Psychobiotics are defined strains with known composition, dosage, and targeted mechanisms, whereas fermented foods contain complex, often undefined microbial consortia that vary with raw materials, fermentation conditions, and storage, creating batch-to-batch variability that complicates reproducibility and strain-specific interpretation. On safety, probiotics are generally well tolerated, and meta-analysis shows no significant increase in total adverse events versus placebo, but a systematic review found greater incidence of abdominal pain in inflammatory bowel disease patients, and rare serious infections with Lactobacillus strains, including bacteremia, have been reported — a particular caution for elderly, frail, or immunocompromised people with dementia. The authors emphasize that many human studies are observational and support associations rather than causation, that most psychobiotic research is short-term, and that future work must prioritize precisely reported strains, adequately powered trials with cognitive endpoints and mechanistic biomarkers, dose-response studies, and long-term safety evaluation before psychobiotics or fermented foods can be recommended as standardized interventions for Alzheimer’s disease.

Subject of Research: The potential role of psychobiotics and fermented foods in modulating the gut-brain axis in Alzheimer's disease

Article Title: Psychobiotics and fermented food interventions targeting the gut-brain axis in Alzheimer’s diseases

Article References: Mabrok, H. B., & Mohamed, D. A. (2026). Psychobiotics and fermented food interventions targeting the gut-brain axis in Alzheimer’s diseases. Discover Aging, 1(1), Article 4. https://doi.org/10.1007/s44518-026-00004-3

Image Credits: AI Generated

DOI: 10.1007/s44518-026-00004-3

Keywords: psychobiotics, probiotics, fermented foods, gut-brain axis, Alzheimer's disease, dementia, gut microbiota, neuroinflammation, amyloid-beta, tau pathology, BDNF, randomized controlled trials